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50The effect of chemotherapy for malignancy on the
natural history of aortic aneurysm
Zenia L. Martin, MD,a Tara M. Mastracci, MD,a Roy K. Greenberg, MD,ay Jose P. Morales, MD,a and
James Bena, MS,b Cleveland, Ohio
Objective: Surgical dogma holds that chemotherapy increases the risk of aneurysm growth and rupture. We sought to
determine the effect of cytotoxic chemotherapy on the growth of aortic aneurysms.
Methods: All patients undergoing chemotherapy for malignancy with coexisting aortic aneurysms at our institution be-
tween 2000 and 2011 were identiﬁed. Review of electronic medical records and rereview of serial cross-sectional imaging
was performed. An additional cohort of patients undergoing aneurysm surveillance during the same period was identiﬁed,
and demographic and anatomic variables were collected. Planned analysis included descriptive analysis, change in aneu-
rysm diameter over time, and association of growth or need for intervention with type of chemotherapy and type of
malignancy.
Results: Between 2000 and 2011, 125 patients at our institution had a concurrent diagnosis of aortic aneurysm and
malignancy requiring cytotoxic chemotherapy. Cross-sectional imaging was available for 91 patients. The predominant
malignancy type was lung cancer (34 of 91 [38%]), followed by lymphoma (21 of 91 [23%]) and colorectal cancer (10 of
91 [11%]). Most aneurysms were infrarenal (53 of 91 [58%]). Most patients were treated with more than one class of
chemotherapeutic agent over 267 days (interquartile range [IQR], 144-469 days), and most had at least one cycle of
alkylating agents (73 of 91), in addition to antimetabolites (42 of 91) and plant alkaloids/terpenoids (40 of 92).
Chemotherapy regimens included steroids in 84 patients (92%). The baseline aneurysm diameter was 41.4 mm (IQR,
34.9-51.3 mm) for patients who received chemotherapeutic agents and 46.0 mm (IQR, 40-52 mm) for those who did
not. Eight of the 91 patients (9%) underwent aneurysm repair during chemotherapy, but only two required urgent repair
due to aneurysm rupture. The rate of aneurysm growth per year for patients who did and did not receive chemotherapy
was similar at 2.3 mm vs 2.4 mm (P [ .69).
Conclusions: In 91 patients over 10 years at our institution, chemotherapy did not increase aneurysm growth compared
with patients not undergoing treatment for malignancy. (J Vasc Surg 2015;61:50-7.)The volume of cross-sectional imaging being per-
formed during the last two decades has increased, with
>80 million computed tomography (CT) scans performed
in the United States alone in 2010.1,2 This has resulted in a
large number of incidental ﬁndings, including aortic aneu-
rysms.3,4 If population-based screening programs can be
extrapolated to this population, most of these aneurysms
are below the threshold for treatment (<5.5 cm) and
should be entered into surveillance programs.5,6 However,
even in these screening studies, there was a small incidence
of rupture during surveillance (0.6% and 1.6%, respectively)
emphasizing the biologic variability of aneurysms.5,6the Departments of Vascular Surgerya and Quantitative Health
iences,b The Cleveland Clinic Foundation.
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ﬁeld of oncology.7 Concurrence of malignancy and aortic
aneurysm occurs due to similar demographics and overlap
in risk proﬁles.8-10 Accelerated aneurysm growth, aortic
dissection, and aneurysm rupture during chemotherapy
are all described in individual patients.11-13 In addition,
many chemotherapeutic regimens include the concurrent
prescription of oral or intravenous corticosteroids, which
themselves have been associated with an increased rate of
aneurysm expansion and spontaneous thoracic aortic aneu-
rysm rupture.14,15
Because of concerns about accelerated growth rates
and rupture of aneurysms during chemotherapy, vascular
surgeons are regularly consulted to consider aneurysm
repair before its initiation. Although a body of evidence ex-
ists that examines other factors that may inﬂuence growth
rates of aortic aneurysms,16,17 the behavior of aortic aneu-
rysm growth rates in patients receiving cytotoxic chemo-
therapy remains unreported. This study examines the rate
of aneurysm growth in patients receiving cytotoxic chemo-
therapy and compares it with patients with aneurysms in a
surveillance program.
METHODS
Inclusion criteria
A retrospective review of the electronic medical record
at our institution was performed to identify all patients
Table I. Criteria to conﬁrm presence of aneurysm
Type of aneurysm Minimum size inclusion criteria (mm)
Abdominal aortic >30
Thoracoabdominal aortic >30
Ascending aortic >40
Thoracic >30
Common iliac >20
Internal iliac >15
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aneurysm and who received cytotoxic chemotherapy for a
malignant process. Electronic patient records were exam-
ined to conﬁrm administration of the drugs. Those who
had not received cytotoxic chemotherapy were excluded.
Three-dimensional imaging was reviewed to conﬁrm a
diagnosis of aneurysm as deﬁned in Table I. Inclusion to
the study required a full three-dimensional imaging set
before and after completion of chemotherapy. Only pa-
tients with a diagnosis of aneurysm and a full imaging
data set were included in the analysis.
Data were collected on a group of patients with aortic
aneurysms attending the outpatient clinic in our institution
for aneurysm surveillance during a similar period (January
2000 to July 2007). Any patient who underwent at least
two CT scans before an intervention was further analyzed.
Of 5274 patients with a primary diagnosis of aortic aneu-
rysm who were reviewed, 4922 patients were excluded
for the following reasons: 1079 had aneurysms not limited
to the infrarenal aorta, and 3843 were treated in the
absence of serial imaging studies or did not return for
follow-up. The remaining 362 patients underwent 1162
CT scans and comprise the comparison control population.
Eight patients were removed from this control group
because of a concurrent diagnosis of cancer, leaving the
ﬁnal number of patients in the control group at 354. The
Cleveland Clinic Institutional Review Board approved the
study. Because it was a retrospective study, patient consent
was not obtained.
Image interpretation
Chemotherapy group. All CT studies were analyzed
using Intuition software (Terarecon, San Mateo, Calif).
When CT scans with contrast were available, centerline of
ﬂow analyses with orthogonal projections were used to
determine maximal diameters. Maximal diameter in non-
contrast scans was established using mutiplanar reconstruc-
tions. Two independent experienced examiners (T.M.M.,
Z.L.M.) read the ﬁrst 100 studies, with a Pearson correla-
tion coefﬁcient of 0.98, and on this basis, all further images
were read by a single observer.
CT scans analyzed for each patient included the ﬁrst
CT scan demonstrating the aneurysm, the CT scan before
commencement of chemotherapy, the CT scan after
chemotherapy, the CT scan before repair in those patients
who underwent aneurysm repair during the study period,
and the most recent CT scan. Data recorded from each
of these scans included the date of the scan, the location
of the aneurysm, and the maximal diameter of the
aneurysm.
Surveillance group. Analysis of CT images occurred
as above. Comparison of 100 CT scans selected randomly
and measured by three interpreting physicians (Z.L.M.,
J.P.M., T.M.M.) tested the accuracy of the measurements.
The mean difference of maximal aneurysm diameter mea-
surement was 0.7 mm (standard deviation, 0.2 mm). Other
variables differed by similar amounts, implying consistency
of measurement.Clinical data collection
Patient demographics, the nature of the malignancy,
the cytotoxic chemotherapy agents used, the duration of
chemotherapy, concurrent steroid use, and laboratory
values were collected from the electronic medical record.
Paper records were examined when further information
was required.
Statistical analysis
All prospective data were captured and stored in an
Excel database (Microsoft Corp, Redmond, Wash) and
were summarized using frequencies and percentages or
medians and ranges or medians and interquartile ranges
(IQRs). Linear models were used to compare the change
between chemotherapy patients and natural history pa-
tients. The last measure in the model was the response,
and the baseline measure, days of follow-up, group, and
the interaction between group and time were used as pre-
dictors. Given the difference in baseline size, the model was
adjusted for baseline size as well. Because the relationship
between days of follow-up and the last measure was
nonlinear, a quadratic factor for this outcome was also
included in the model. Analyses were performed using
SAS 9.2 software (SAS Institute Inc, Cary, NC) and R soft-
ware (The R Foundation for Statistical Computing,
http://www.r-project.org/foundation/), and a signiﬁ-
cance level of 0.05 was assumed for all tests. Univariate
and multivariate analysis was not performed because of
the low event rate of growth in the chemotherapy group.
RESULTS
Patient demographics. Between January 2000 and
July 2011, 125 patients at our institution had a concurrent
diagnosis of aortic aneurysm and malignancy requiring
cytotoxic chemotherapy. A full cross-sectional imaging
data set was not available for 34 of these patients, so they
were excluded from the analysis. Patient demographics and
clinical information for the 91 patients included in the
study are summarized in Table II. During a similar interval,
data were collected for 362 patients at our institution who
were undergoing surveillance for infrarenal abdominal
aortic aneurysms (AAAs). Eight of these patients received
cytotoxic chemotherapy during surveillance and were
included in the study group. Patient demographics and
clinical information for the 354 patients included in the
analysis are summarized in Table II.
Table II. Demographic information for the chemotherapy and natural history cohorts
Factora Total (N ¼ 445) Natural history (n ¼ 354) Chemotherapy (n ¼ 91) P valueb
Age, years 72.0 (67.0-78.0) 72.0 (67.0-78.0) 70.0 (66.0-77.0) .14
Gender .59
Male 363 (82) 287 (81) 76 (84)
Female 82 (18) 67 (19) 15 (16)
Hyperlipidemia 286 (64) 231 (65) 55 (60) .39
CADc 269 (61) 226 (64) 43 (47) .004
Diabetes mellitus 80 (18) 61 (17) 19 (21) .42
Heart failurec 124 (28) 100 (28) 24 (26) .71
Strokec 93 (21) 61 (17) 32 (35) <.001
COPD 144 (32) 110 (31) 34 (37) .25
Dialysisc 8 (2) 5 (1) 3 (3) .23
Statin 292 (66) 224 (63) 68 (75) .040
b-blocker 301 (68) 218 (62) 83 (91) <.001
ACE inhibitor 183 (41) 127 (36) 56 (62) <.001
Death 120 (27) 75 (21) 45 (50) <.001
ACE, Angiotensin-converting enzyme; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease.
aValues are presented as median and interquartile range (IQR) for continuous data and as number (%) for categoric data.
bP values are from Wilcoxon rank sum tests and Pearson c2. P < .05 indicates statistical signiﬁcance.
cData not available for all patients.
Table III. Aneurysm type in the chemotherapy and
natural history cohorts
Location of aneurysm
Natural history,
No. (%)
Chemotherapy,
No. (%)
Thoracoabdominal 0 17 (19)
Infrarenal aorta 345 (100) 53 (58)
Thoracic aorta 0 2 (2)
Ascending aorta 0 9 (10)
Iliac 142 (40) 9 (10)
Other 0 1 (1)
Table IV. Types of malignancies
Malignancy type No. (%)
Lung 34 (38)
Lymphoma 21 (24)
Colon 10 (12)
Bladder 5 (6)
Leukemia 3 (3)
Pancreas 2 (2)
Head and neck 2 (2)
Myeloma 2 (2)
Gastric 2 (2)
Esophagus 2 (2)
Cervix 2 (2)
Unknown primary 2 (2)
Ovarian 1 (1)
Prostate 1 (1)
Small bowel 1 (1)
Table V. Chemotherapeutic agents
Chemotherapeutic agents No. (%)
Alkylating agents 73 (80)
Antimetabolites 42 (46)
Plant alkaloids and terpenoids 40 (44)
Topoisomerase inhibitors 15 (16)
Cytotoxic antibiotics 15 (16)
Monoclonal antibodies 33 (36)
Others (any) 13 (14)
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aneurysms in patients undergoing chemotherapy were
infrarenal (53 of 91 [58%]) and thoracoabdominal (17 of
91 [19.5%]), with a mean prechemotherapy aneurysm
size of 40.7 mm (range, 20.6-66.4 mm). A complete list
of aneurysm types is in Table III. Seventeen patients(18%) had undergone a previous aneurysm repair, and
seven patients had evidence of a previous aortic dissection.
The predominant malignancy type was lung cancer (34
in 91 [38%]), followed by lymphoma (21 of 91 [23%]) and
colorectal cancer (10 of 91 [11%]). A complete list of ma-
lignancies is presented in Table IV.
Most patients were treated with more than one class of
chemotherapeutic agent over an average of 267 days (IQR,
144-469 days), and most had at least one cycle of alkylating
agents (73 of 91), in addition to antimetabolites (42 of 91)
and plant alkaloids/terpenoids (40 of 91; Table V).
Chemotherapy regimes included steroids in 92% (84 of
91) of patients.
Eight of 91 patients (9%) underwent aneurysm repair
during chemotherapy, but only two required emergency
repair of their aneurysms (Table VI). The ﬁrst patient had
a lung tumor and commenced systemic chemotherapy
with an alkylating agent and a topoisomerase inhibitor. He
was receiving concurrent steroid therapy. His prechemo-
therapy scan demonstrated a 41-mm infrarenal AAA. He
presented to the emergency department 8 weeks later with
severe abdominal pain. A CT scan showed a maximal diam-
eter of 51 mm with rupture of the aneurysm. He underwent
an emergency endovascular repair of his aneurysm that day.
He went on to complete his course of chemotherapy.
Table VI. Patients requiring intervention during chemotherapy
Patient Aneurysm type Malignancy
Aneurysm size
prechemo
(mm)
Aneurysm
size at time
of intervention
(mm) Symptoms
Intervals between
prechemo scan and
repair (months)
Chemotherapeutic
agents Steroids
1 Infrarenal Lymphoma 62 66 No 4 Multiple Yes
2 Ascending Myeloma 65 66 No 12 Monoclonal antibody Yes
3a Infrarenal Lung 41 51 Pain,
rupture
3 Topoisomerase inhibitor
Alkylating agent
Yes
4a Infrarenal Lung 60.4 65.4 Pain,
rupture
2 Topoisomerase inhibitor
Alkylating agent
Yes
5 Iliac Prostate 45.6 46 No 1 Other No
6 Infrarenal Lung 53 56 No 6 Alkylating agent Plant
alkaloids
Yes
7 Ascending Lymphoma 42 45 No 20 Multiple agents Yes
8 Thoracoabdominal Leukemia 57 63 No 19 Antimetabolites
Cytotoxic antibiotics
Yes
aPatients required emergency repair of their aneurysm.
Fig 1. The pattern of change is shown for the two groups. The P value is testing whether the pattern of change differs
between groups. The model assumes baseline size of 40 mm.
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commenced chemotherapy with an alkylating agent and a
topoisomerase inhibitor. He was also receiving concurrent
steroids. His prechemotherapy scan demonstrated a 60-
mm infrarenal AAA. He presented with collapse exactly
1 month after commencement of chemotherapy, and his
CT scan showed a maximal aortic diameter of 65 mm
with rupture. He underwent an endovascular repair of his
aneurysm. He was discharged but was readmitted with
acute renal failure and a large retroperitoneal hematoma,
and a decision was made for palliative care.
The aneurysm growth rate per year of patients
receiving chemotherapy was 2.3 mm. When growth rates
between larger aneurysms (>5 cm) and smaller aneurysms(<5 cm) were assessed, patients with larger aneurysms had
signiﬁcantly larger growth (6.4 mm vs 2 mm; P ¼ .005).
Surveillance group. All patients in the surveillance
group had an infrarenal AAA, with iliac involvement in
40%. The mean follow-up for these patients was
22 months. A total of 1162 CT scans were reviewed
(mean, 3.3 scans; range, 2-12 scans).
A total of 164 patients underwent aortic repair due to
aneurysm growth >5.5 cm. Ten of these patients required
urgent intervention for symptoms, including rupture. All
but one of the patients who underwent repair had aneu-
rysms $55 mm. The mean follow-up for this group was
26 months (standard deviation, 24 months). The baseline
aortic diameter was 46.0 mm, with a growth rate of
Fig 2. The pattern of change for aneurysms conﬁned to the infrarenal segment is shown for the two groups. The P
value is testing whether the pattern of change differs between groups. The model assumes baseline size of 40 mm.
Table VII. The results from the linear regression model
predicting follow-up size are shown based on baseline
size, group, follow-up length, and the interactions
between group and time
Factor Estimate Standard error P value
Intercept 1.62 1.11 .14
Baseline measure 1.07 0.02 <.001
Follow-up (per year) 2.19 0.19 <.001
Follow-up (per year) 0.10 0.05 .036
Chemotherapy 0.11 0.69 .87
Follow-up  chemo 0.58 0.42 .16
Follow-up2  chemo 0.48 0.74 .52
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whereas the baseline aortic diameter for those who did
not meet the primary outcome was 47, with a yearly
growth rate of 2.8 mm/y (P ¼ .002).
The annual aneurysm growth rate of patients in the
surveillance group was 2.4 mm/y. When growth rates be-
tween larger aneurysms (>5 cm) and smaller aneurysms
(<5 cm) were assessed, those with larger aneurysms had
signiﬁcantly larger growth (3.1 mm vs 2.1 mm; P ¼ .003).
Growth rate comparison. The baseline aneurysm
diameter for patients on and not on chemotherapeutic
agents was 41.4 mm (IQR, 34.9-51.3 mm) and
46.0 mm (IQR, 40-52 mm), respectively. The annual
rate of aneurysm growth for patients on and not on chemo-
therapy was similar (2.3 mm/y vs 2.4 mm/y; P ¼ .09;
Fig 1). A subanalysis of patients with aneurysms limited
to the infrarenal aorta again showed no difference in
aneurysm growth between patients on and not on
chemotherapy (2.1 mm/y vs 2.4 mm/y; P ¼ .86; Fig 2
and Table VII).
DISCUSSION
In the published literature, factors associated with an
increased rate of AAA expansion are aneurysm size, smok-
ing, chronic obstructive pulmonary disease, female gender,
and hypertension.18 Other putative factors include steroid
use and chemotherapy and are described in individual
case reports.11,13,14 In this study, which reﬂects a 10-year
experience in an academic center, we report no apparent
difference in growth between patients on and not on
chemotherapy. We also reinforce the low rupture risk of
aneurysms <5 cm with a more robust imaging surveillance
program. Although our data set is small, it represents the
only reported series in the literature to date.Individual case reports of accelerated growth and
aneurysm rupture during chemotherapy have postulated
that chemotherapeutic agents may alter the biologic
framework of both the normal and aneurysmal aorta,
leading to increased growth rates during treatment.
The hypotheses have included disturbed synthesis of
DNA, elastin and collagen, the release of cytokines, the
inhibition of smooth muscle cell proliferation, and induc-
tion of matrix metalloproteinases as effects of chemother-
apeutic drugs that might induce AAA growth and
rupture. To date, one aneurysm rupture and a further
case of rapid aortic expansion during chemotherapy
have been described.11,13 We describe two further cases
of aneurysm growth and rupture in our series, consistent
with a total 3% (2 of 91) rupture rate during chemo-
therapy (Table VIII). Two of these four patients had an-
eurysms above the recommended threshold for treatment
according to the current guidelines when they started
their chemotherapy. However, both had unresectable
Table VIII. Literature review of chemotherapy and ruptured aneurysms
First author Malignancy
Aneurysm
growth (mm)
Time period of
growth (months) Chemotherapy agents Steroids Outcome
Palm,13 2000 Pancreatic 58-71 13 Nucleoside analog, alkylating agent Yes Rupture; open repair
Zanow, 200011 Gastric 17-53 5 Plant alkaloid, alkylating agent, and
pyrimidine analog
NA Rupture; endovascular
repair
Current series Lung 41-51 2 Alkylating agent, topoisomerase
inhibitor
Yes Rupture; endovascular
repair
Current series Lung 60-65 1 Alkylating agent, topoisomerase
inhibitor
Yes Rupture; endovascular
repair
NA, Not available.
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made in each case to defer elective aneurysm repair.
The dilemma of emergency treatment in this setting is
that malignant comorbidities may alter outcomes of aneu-
rysm repair. Although both patients underwent successful
aneurysm repairs (one open and one endovascular), neither
survived more than 1 month because they died of
malignancies.
The two other published previously cases highlight a
second issue.11,13 The ﬁrst of these patients had a
normal-caliber aorta (17 mm) on completion of chemo-
therapy, and 5 months later he presented with a symptom-
atic 53-mm infrarenal AAA that required repair. Our
second patient had a 41-mm AAA before starting chemo-
therapy with an alkylating agent and a topoisomerase in-
hibitor, and 8 weeks later he presented with a ruptured
51-mm AAA. Both patients underwent successful endo-
vascular repairs; however, neither patient would have
been considered for repair before the index presentation
with rupture. Given the a rupture rate of just 1.5% (one
of 62) in this series of aneurysms below the threshold for
intervention before chemotherapy commencement, this
likely represents the biologic variability we see normally
with aneurysm disease and should not be grounds for
recommendation of repair of small aneurysms before
chemotherapy commencement.
Many of the current chemotherapeutic strategies for
the treatment of malignancy involve the concurrent admin-
istration of corticosteroids. Cases of aneurysm rupture in
patients with connective tissue disorders are plentiful in
the literature.19,20 Although long-term steroid regimens
have a protective effect on their primary condition, detri-
mental effects are also hypothesized, including hyperten-
sion, hyperlipidemia, hyperglycemia, and negative effects
on collagen formation and connective tissue strength that
may predispose to increased aneurysm growth and
rupture.21 Two cases of ruptures after short-term treatment
with glucocorticoids for disorders not causing weakness of
connective tissue are also described14; however both of
these patients had additional risk factors for aneurysm
rupture, including advanced age. In addition, the four pa-
tients we have described received a corticosteroid concur-
rently with their chemotherapy, so it may be that
chemotherapy regimens should be altered to avoid theuse of corticosteroids in patients with large aneurysms
not ﬁt for surgery.
Not all chemotherapeutic agents, however, have a
disadvantageous effect on the growth rate of aneurysms.
The potential protective effects of chemotherapeutic agents
on small aneurysms has been proposed. Statins, b-blockers,
angiotensin-converting enzyme (ACE) inhibitors, and anti-
biotics are among the chemotherapeutic agents that have
been explored for potential therapeutic use in the preven-
tion of aneurysm growth. Indeed the chemotherapy group
in our study had a higher incidence of statin, b-blocker, and
ACE inhibitor use that may have inﬂuenced the rate of
growth in this group. Early animal studies showed promise
for propranolol as a therapeutic strategy; however, several
randomized controlled trials (RCTs) failed to support these
results, although both RCTs suffered from high rates of
noncompliance.16,22
Statin therapy is associated with a reduction in the pro-
gression of atherosclerosis and with improved clinical out-
comes in cardiovascular disease. Although there is an
association between the presence of AAA and total choles-
terol, studies have failed to show a clear relationship be-
tween total cholesterol and AAA growth rate.23,24 Animal
studies suggest, however, that statins may inﬂuence aneu-
rysm growth rates.25 Two small observational studies sug-
gest a decrease in aneurysm growth rate in patients
receiving statin therapy; however, the potential for bias in
these studies is large.26,27 Given that many patients with
aneurysms already have valid reasons to be receiving statin
therapy, designing more robust studies to look particularly
at the protective role of statins on aneurysm growth may
prove challenging.
Several animal experiments have suggested a link be-
tween the renin-angiotensin axis and aneurysm develop-
ment.28,29 There is signiﬁcant disparity in the results from
all the clinical studies, however, meaning RCTs are neces-
sary to elucidate the true effect that ACE inhibitors might
have on protection from aneurysm growth and
rupture.17,27,30,31
Hypertension, smoking, chronic obstructive pulmo-
nary disease, and female gender are the most common
risk factors known to predict fast growth in AAA, whereas
diabetes mellitus and peripheral arterial disease (PAD) have
been shown to slow the growth rates of AAA.18,31,32 The
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dian growth rate of 0.32 cm/y, with the only signiﬁcant
univariate predictors of an increased rate of enlargement
being a larger initial diameter and the absence of diabetes
mellitus.6 Similarly, the UK Small Aneurysm Trial showed
a growth rate of 0.33 cm/y in the surveillance group, with
a mean risk of rupture of 1% for AAAs between 4.0 and
5.5 cm.5 In our study, we demonstrated a growth rate of
0.23 cm/y in patients who received chemotherapy. This
growth rate did not differ from the overall growth rate in
our control group of 0.22 cm/y.
Because this is a retrospective review, it holds with it all
the caveats applied to data not prospectively collected. In
those patients whose aneurysms reached the surgical
threshold, we did not have in-depth information on the
surgical decision making nor was it standardized. The rela-
tively small numbers of patients in each of the aneurysm
groups in the chemotherapy group meant it was not
possible to subanalyze the growth rates in each group sepa-
rately. Aneurysm-related mortality could not be calculated
because a large number of patients in the study group were
lost to follow-up.
This series does, however, represent the only series in
the literature addressing the issue of AAA growth during
chemotherapy, an important clinical factor. In addition,
our control group represents the ﬁrst large series regarding
the natural history of AAA based on standardized aortic
protocol CT scan with 3D reconstruction software and
centerline of ﬂow acquisition. These more accurate data
reinforce the very low rupture rate of aneurysms of <5 cm.
CONCLUSIONS
AAA growth rates do not appear to be different in pa-
tients receiving cytotoxic chemotherapy compared with
controls. Individual cases of rapid growth and rupture
while receiving chemotherapy likely represent the normal
biologic variability we see with aneurysm disease. We
recommend adhering to the current guidelines for
threshold for surgical repair, because there is no evidence
to support repair of small aneurysms.
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